Phenazepam's safety pharmacogenetic study results: influence of CYP2C9, CYP3A5, CYP2C19, ABCB1 and CYP3A4/5 isoenzymes' activity

被引：0
|
作者：
Ivashchenko, D. [1 ]
Ryzhikova, K. [2 ]
Sozaeva, Z. [2 ]
Grishina, E. [2 ]
Zastrozhin, M. [3 ]
Bryun, E. [3 ]
Sychev, D. [4 ]
机构：
[1] Russian Med Acad Continuous Profess Educ, Dept Appl Problems Personalized Med, Moscow, Russia
[2] Russian Med Acad Continuous Profess Educ, Dept Mol Biol Studies, Moscow, Russia
[3] Russian Med Acad Continuous Profess Educ, Dept Narcol, Moscow, Russia
[4] Russian Med Acad Continuous Profess Educ, Dept Clin Pharmacol, Moscow, Russia
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2018年 / 28卷
关键词：
D O I：
10.1016/j.euroneuro.2017.12.037
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.1.019
引用
收藏
页码：S17 / S18
页数：2
相关论文
共 50 条
  • [1] Pharmacogenetics of acenocoumarol:: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements
    Saraeva, R. B.
    Paskaleva, I. D.
    Doncheva, E.
    Eap, C. B.
    Ganev, V. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (06) : 641 - 649
  • [2] Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements (vol 32, pg 641, 2007)
    Saraeva, R. B.
    Paskaleva, I. D.
    Doncheva, E.
    Eap, C. B.
    Ganev, V. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (01) : 93 - 93
  • [3] Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population
    Krasniqi, Valon
    Dimovski, Aleksandar
    Bytyqi, Hasime Qorraj
    Eftimov, Aleksandar
    Simicevic, Livija
    Bozina, Nada
    ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, 2017, 68 (03): : 180 - 184
  • [4] Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians
    Fabiana B. Kohlrausch
    Ángel Carracedo
    Mara H. Hutz
    Molecular Biology Reports, 2014, 41 : 1453 - 1460
  • [5] Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians
    Kohlrausch, Fabiana B.
    Carracedo, Angel
    Hutz, Mara H.
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (03) : 1453 - 1460
  • [6] Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry
    Falzoi, Matteo
    Mossa, Alessandra
    Congeddu, Elena
    Saba, Luisella
    Pani, Luca
    PHARMACOGENOMICS, 2010, 11 (04) : 559 - 571
  • [7] Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel
    Henningsson, A
    Marsh, S
    Loos, WJ
    Karlsson, MO
    Garsa, A
    Mross, K
    Mielke, S
    Viganò, L
    Locatelli, A
    Verweij, J
    Sparreboom, A
    McLeod, HL
    CLINICAL CANCER RESEARCH, 2005, 11 (22) : 8097 - 8104
  • [8] CYP2D6, CYP2C19, CYP2C9 and CYP3A5 polymorphism in the Spanish population
    Llovo, R.
    Tudoli, I
    Carril, J. C.
    Fernandez-Novoa, L.
    Seoane, S.
    Cacabelos, R.
    NEW TRENDS IN ALZHEIMER AND PARKINSON RELATED DISORDERS: ADPD 2009, 2009, : 53 - 57
  • [9] Suppression of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 activity by a cocktail of inflammatory cytokines
    Foster, John
    Webber, Guy
    Ormsby, Terry
    Cheung, Yen-Ling
    Paul, Danny S.
    Webber, Colin
    Waring, Adrian
    DRUG METABOLISM REVIEWS, 2016, 48 : 89 - 89
  • [10] The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population
    Liou, Ya-Huei
    Lin, Chien-Ting
    Wu, Ying-Jye
    Wu, Lawrence Shih-Hsin
    JOURNAL OF HUMAN GENETICS, 2006, 51 (10) : 857 - 863
12345